Lyndavel
Manufacturer
Distributor Contents Indications Dosage & Administration Contraindications Special Precautions Adverse Drug Reactions Side Effects Drug Interaction Pregnancy Category (US FDA) Storage Mechanism of Action MIMS Class ATC Classification Regulatory Classification |
Umeda
DKT Medroxyprogesterone acetate Contraception in women and for the treatment of menorrhagia and secondary amenorrhea, mild to moderate endometriosis. Administer the injection on the 1st day of menstrual bleeding or start any day for as long as not pregnant but use condom for the next 7 days. Contraception: A single dose (medroxyprogesterone acetate 150 mg in 1 mL suspension) IM injection in the upper buttocks (gluteal muscle, upper outer portion) or upper arm (deltoid muscle) is given every 3 months. Treatment of Mild to Moderate Endometriosis: Usual Dose: 50 mg weekly or 100 mg every 2 weeks by IM injection. The recommended treatment continues for 90 days up to 6 months. Medical and gynecological examination should be performed before starting Lyndavel. Start administering Lyndavel on the 1st day of menstrual period, 6 weeks after giving birth or any day for as long as not pregnant but use condom for the next 7 days. The common dose of Lyndavel 150 mg is injected deeply into the buttocks or upper arm every 3 months. The next injection should be administered 2 weeks before or after the scheduled day. Sterile technique must be observed to help prevent infection. Disposable syringe and needle must be used. The full dose must be administered to provide adequate absorptive amount. Do not massage the injection site. This could cause Lyndavel to be absorbed too fast. Women with undiagnosed vaginal bleeding and has a history or current high risk of arterial disease. It should generally be avoided in women with hepatic impairment, especially if severe. Lyndavel should not be given in women with porphyria. Use in pregnancy: Prior to starting Lyndavel, pregnancy must be ruled out. Before taking hormonal contraceptives, undergo an appropriate medical examination and medical history carefully evaluated. Regular examination is recommended during use. The contraceptive effectiveness of hormonal contraceptives may be reduced during episodes of vomiting or diarrhea. During this period, using condom may be necessary for 7 days after recovery to avoid pregnancy. Caution use in cardiovascular or renal impairment, diabetes mellitus, asthma, epilepsy, migraine or other conditions which may be aggravated by fluid retention. It should also be used with care if there is a history of depression. High doses should also be used with caution by women susceptible to thromboembolism. Use in lactation:Lyndavel has no negative influence during lactation. Infants whose mothers are receiving the injection while breastfeeding appear to develop normally, both physically and mentally. Breastfeeding women should wait 6 weeks after giving birth before starting to use Lyndavel. Nausea, vomiting, headache, breast discomfort, depression, skin rashes & slight wt change, menstrual irregularities eg amenorrhea, breakthrough bleeding, spotting & menorrhagia. Glucocorticoid effects. Some women may experience side effects eg, nausea, vomiting, headache, breast discomfort, depression, skin rashes and slight weight change. Menstrual irregularities eg, amenorrhea, breakthrough bleeding, spotting and menorrhagia are common with progesterone-only contraceptives. Women who are using Lyndavel have lesser risk for thromboembolic and cardiovascular disease than those using combined oral contraceptives. Lyndavel may have glucocorticoid effects when given long-term at high doses. Most of these side effects are mild and usually disappear after a few months of contraceptive use. Enzyme-inducing drugs eg carbamazepine, griseofulvin, phenobarb & rifampicin may reduce the efficacy of medroxyprogesterone acetate. Aminoglutethimide markedly reduces the plasma conc of medroxyprogesterone acetate. Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. Store at a temperature not exceeding 30°C. Lyndavel is a progestin-only injectable contraceptive that gives 3 months of contraceptive protection. It contains medroxyprogesterone acetate, a derivative of progesterone. It contains a progestin that is similar to the natural hormone that a woman's body produces. This hormone is released slowly into the bloodstream. Lyndavel stops ovulation, thins the lining of the uterus and thickens the cervical mucus. In combination, these actions prevent pregnancy. Lyndavel only works for about 3 months. The shot must be repeated every 3 months to prevent pregnancy. After stopping from using Lyndavel, normal ovarian functions return after a short time. Lyndavel can be safely used by breastfeeding mothers. Pharmacokinetics: Medroxyprogesterone is absorbed from the GIT. In the blood, it is highly protein bound, principally to albumin. It is metabolized in the liver and excreted mainly as glucuronide conjugates in the urine and feces. It has a t½ of 24-30 hrs after oral doses; the t½ may be as long as 50 days after IM injection. Oestrogens, Progesterones & Related Synthetic Drugs / Depot Contraceptives G03AC06 - medroxyprogesterone ; Belongs to the class of progestogens. Used as systemic contraceptives. Rx |